With the introduction of genAI tool Elsa at the FDA in June, the technology is playing a greater role in the medical device review process.

The Company renewed its Normal Course Issuer Bid (NCIB) on February 24, 2025. During the six months ended June 30, 2025, the Company purchased and cancelled 80,600 shares under the NCIB at an average ...

To explore the valuable insights in the Patient-Derived Xenograft Model Market report, you can easily download a sample PDF of the report – https ... rates of clinical trials and expedite the ...